Skip to content
Global sound
The Bio Report

The Bio Report

Engineering T-Cell Engagers for Solid Cancers

· 32 min · Episode 191

Show notes

T-cell engagers have delivered important advances in blood cancers, but extending their success to solid tumors has proved considerably more difficult. Physical barriers, immunosuppressive tumor microenvironments, and the risk of attacking healthy tissue have constrained the field. Deck Bio is developing multi-target T-cell engagers to address these limitations. Jack Silberstein, the company’s CEO, discusses Deck Bio’s efforts to create therapies that reach more cancer cells, reduce the likelihood that tumors will evade treatment, and minimize harm to healthy tissue.

Website: thebioreport.podbean.com

Live, last hour: 6,913 songs on 3,075 stations in 129 countries

Discover the world through radio

More ways to discover (9)

Heard something good? Save it, or open it straight away in Spotify.

Radio 538 luisteren - Live!Popular right now